ESR1 and breast cancer: Our current and published results place MLK3 as one of the key downstream molecules in E2-mediated breast cancer cell survival pathways and identification of specific mediators that antagonize its expression might serve as feasible targets to promote cell death in ER+ breast cancer cells.